Structure Therapeutics is trading 4.22% down at $22.90; no company-specific announcement explaining the October 13 move surfaced, and biotech-sector pressure is a plausible contributor.
- The prior session also ended lower, at $23.91, down 6.38%.
- Biotech ETF XBI was reported down 2.01% during the regular session, while major indexes were only modestly lower. No direct catalyst for the stock’s decline is confirmed.